Human mesenchymal stromal cells (hMSC) are adult stem or progenitor cells, which physiological role is reparation of damaged tissues. This is achieved mostly by secretion of trophic, angiopoietic and immunomodulatory factors. Beside this, hMSC have potential to differentiate in vitro into specialized cells, especially of the mesodermal lineages. Human MSC also significantly support hematopoiesis in hematopoietic niche. This knowledge raised high hopes for therapeutic use of hMSC, especially in regenerative medicine and treatment of autoimmune diseases, including graft versus host disease (GvHD). As a proof of concept served initially crude preparations of bone marrow mononuclear cells (BMMC), which contain small numbers of hMSC. In our hospital, two pilot clinical studies with BMMC were performed: study of treatment of acute myocardial infarction (negative, prematurely terminated) and study of treatment of peripheral leg arthery disease (promising results). Further research was aimed on optimalisation of hMSC cultivation method for clinical use to obtain highest possible yield and get free from animal proteins. Human MSC were traditionally cultivated in research-grade media with fetal calf serum (FCS), which can lead to immunization of patients after repeated application of hMSC. We achieved...
| Identifer | oai:union.ndltd.org:nusl.cz/oai:invenio.nusl.cz:372372 |
| Date | January 2017 |
| Creators | Pytlík, Robert |
| Contributors | Trněný, Marek, Filová, Elena, Lesný, Petr |
| Source Sets | Czech ETDs |
| Language | Czech |
| Detected Language | English |
| Type | info:eu-repo/semantics/doctoralThesis |
| Rights | info:eu-repo/semantics/restrictedAccess |
Page generated in 0.0016 seconds